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DNA-tumor virus entry-From plasma membrane to the nucleus
Abstract
DNA-tumor viruses comprise enveloped and non-enveloped agents that cause malignancies in a large
variety of cell types and tissues by interfering with cell cycle control and immortalization. Those
DNA-tumor viruses that replicate in the nucleus use cellular mechanisms to transport their genome and
newly synthesized viral proteins into the nucleus. This requires cytoplasmic transport and nuclear import
of their genome. Agents that employ this strategy include adenoviruses, hepadnaviruses, herpesviruses,
and likely also papillomaviruses, and polyomaviruses, but not poxviruses which replicate in the
cytoplasm. Here, we discuss how DNA-tumor viruses enter cells, take advantage of cytoplasmic
transport, and import their DNA genome through the nuclear pore complex into the nucleus.
Remarkably, nuclear import of incoming genomes does not necessarily follow the same pathways used
by the structural proteins of the viruses during the replication and assembly phases of the viral life cycle.
Understanding the mechanisms of DNA nuclear import can identify new pathways of cell regulation and
anti-viral therapies.
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Abstract 
DNA-tumor viruses comprise enveloped and nonenveloped agents that cause 
malignancies in a large variety of cell types and tissues by inferfering with cell cycle 
control and immortalization.  Those DNA-tumor viruses that replicate in the nucleus 
use cellular mechanisms to transport their genome and newly synthesized viral 
proteins into the nucleus.  This requires cytoplasmic transport and nuclear import of 
their genome.  Agents that employ this strategy include adenoviruses, 
hepadnaviruses, herpesviruses, papillomaviruses, and polyomaviruses, but not 
poxviruses which replicate in the cytoplasm.  Here, we discuss how DNA-tumor 
viruses enter cells, take advantage of cytoplasmic transport, and import their DNA 
genome through the nuclear pore complex into the nucleus.  Remarkably, nuclear 
import of incoming genomes does not necessarily follow the same pathways used by 
the structural proteins of the viruses during the replication and assembly phases of 
the viral life cycle.  Understanding the mechanisms of DNA nuclear import can 
identify new pathways of cell regulation and anti-viral therapies.   
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Medical and epidemiologic records indicate that 12–20% of the human cancer 
incidences worldwide are associated with viral infections (1).  These infections are 
mostly due to DNA-tumor viruses, the flavivirus hepatitis C virus (HCV), and 
retroviruses, such as the human T lymphotropic virus type 1 (HTLV-1), a slow 
transforming RNA retrovirus associated with adult T-cell leukemia (2-5).  A variety of 
viruses induce tumors in animals and a few of them have been recognized by the 
International Agency for Research in Cancer (IARC) as human carcinogens (6).  
DNA-tumor viruses are a diverse group of agents grouped into twenty-two families of 
double-stranded DNA-viruses infecting vertebrates and invertebrates but not plants 
(Tab. 1) (International Committee on Taxonomy of Viruses, 
http://www.ictvonline.org/index.asp).  Their capsid sizes range from 30 nm in the 
case of Hepatits B virus (HBV) up to 150 nm for Epstein Barr virus (EBV).  Their 
genomes are linear, for example adenovirus, or circular such as SV40.  They can be 
non-enveloped, such as adenoviridae, papillomaviridae, polyomaviridae, or 
enveloped, such as herpesviruses and hepadnaviruses.  
 
Human Adenovirus type 12 (Ad12) was the first human virus recognized to be 
oncogenic when it was found to cause malignant tumors after inoculation into 
newborn hamsters (7) (Tab. 1).  Later, it was shown that Ad12 integrates its DNA 
into the host chromosomes (8).  Up to now, no epidemiologic evidence has been 
reported of adenovirus-associated malignancies in humans, although a recent study 
detected Ad-DNA in pediatric brain tumors (9).   
 
Herpesviruses are classified into three subfamlies, alpha-, beta- and gamma-
herpesviruses (10), some of which have been associated with human cancers of 
epithelia and lymphatic cells (11, 12) (Tab. 1).  The chicken alpha-herpesvirus 
Marek’s disease virus causes T cell tumors, neurological disease and immune 
suppression in its natural host (13).  The beta-herpesvirus human cytomegalovirus 
(HCMV) is associated with glioblastoma (for a recent discussion, see 14) but has so 
far not been observed to transform normal cells into cancerous cells.  The gamma-
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herpesvirus Epstein Barr virus (EBV) was the first virus shown to induce human 
tumors, nasopharyngeal carcinoma (15). 
 
Papillomaviruses are the causative agents of skin warts, laryngeal papillomas and 
cervical carcinoma, and occur in skin cancers and head and neck sarcomas (16) 
(Tab. 1).  Sexually transmitted human HPVs infect the genital tract, and are classified 
as ‘low risk’ or ‘high risk’ based on their capability to cause cervical carcinoma.  
Among the high risk papilloma viruses, HPV16 is a major cause of cervical cancer 
(17) and infects basal keratinocytes of mucosal epithelia that undergo differentiation.  
 
Members of the polyomavirus family have tumorigenic potential which was initially 
shown for SV40 (18) (Tab. 1).  SV40 causes oncogenic transformation in 
nonpermissive rodent hosts, although not in its natural host, the rhesus macaque.  
Other members of the polyomaviruses have been implicated in the etiology of rare 
neuronal tumors (19).  Most recently, an aggressive human skin cancer, Merkel cells 
carcinoma has been linked to a previously unknown polyomavirus, the Merkel cell 
polyomavirus (MCPyV) (20).  In addition, hepadnaviruses that replicate through an 
RNA intermediate have been associated with hepatocellular carcinoma (21) (Tab. 1).   
 
Here we discuss the mechanims of nuclear transport and import of viral genomes 
during the early phases of DNA-tumor virus infections.  Nuclear import of viral 
structural proteins and transforming proteins has been extensively reviewed in the 
recent past (22-25).  For nucleocytoplasmic transport of RNA from DNA-tumor 
viruses we refer to recent reviews on adenoviruses (25, 26), herpesviruses (27-29), 
papillomaviruses and polyomaviruses (30) and hepadnaviruses (31).  
 
 
2. DNA-tumor virus entry into cells 
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Virus entry into cells is a stepwise process which has been studied in some detail in 
cultured cells (see e.g., 22, 32, 33).  For a schematic view of a generic entry 
pathway, see Fig. 1.  In certain primary cells or explant cultures, they have been 
more difficult to study due to strong innate host anti-virus responses, and the limited 
availability and batch-to-batch variations of these cells.  Nonetheless, there are a 
number of entry steps that are universally required for infection of diverse cell types 
with human or prototypic DNA-tumor viruses, including virus attachment to a receptor 
at the cell surface (for recent reviews, see 34, 35-40), and lateral movements of the 
virus-receptor complex to specialized sites on the plasma membrane (reviewed in 
41, 42).  These lateral movements can lead the virus particles, for example, to tight 
and adherens junctions, where additional receptors are localized, such as CAR for 
adenoviruses, or nectins for herpesviruses (34).   
 
The lateral junctions not only maintain cell adhesion but also regulate epithelial and 
endothelial cell proliferation.  This is reflected in the observation that deregulated cell 
adhesion is a hallmark of invasive tumors.  Recently it has been suggested that a 
ubiquitin ligase of KSHV targets vascular endothelial cadherin for ubiquitin-mediated 
degradation (43).  Cadherin degradation leads to rearrangements of the actin 
cytoskeleton and disregulated transendothelial barriers, which could open the gate 
for additional viruses and increase tumorigenicity.  These features are reminescent 
of the HBV protein HBx which promotes hepatocellular carcinoma by enhancing the 
degradation of the extracellular matrix (44) and downregulating cadherin (45).   
 
The surface-bound DNA-tumor viruses are in many cases taken up by endocytic 
processes or direct penetration through the plasma membrane (38, 46-55), or they 
may fuse their envelope with the limiting endosomal membrane (36, 56).  
Endocytozed nonenveloped viruses can penetrate the limiting endosomal membrane 
(32, 57, 58), or a membrane of the endoplasmic reticulum (59, 60).  For example, 
papillomaviruses are taken up by endocytosis, and released from endosomes upon 
proteolytic cleavage of the minor capsid protein L2 by cellular furin proteases (61, 
62).  L2 remains associated with the viral DNA and ends up in the nucleus near 




3. Bidirectional cytoplasmic transport of incoming virus particles 
provides a mechanism to reach the nucleus 
 
Cytoplasmic transport of DNA-tumor viruses or prototypic DNA-tumor viruses has 
been studied in some detail, most prominently with HSV1 (64, 65) and Ad2/5 (66-69).  
These viruses take advantage of the microtubule-based motor protein complex 
dynein/dynactin to the minus ends of microtubules near the nucleus (for reviews, see 
70, 71, 72).  EBV likely follows the same route on microtubules to the nucleus as 
HSV1 because its capsid protein BFRF3, a homologue of the HSV capsid protein 
UL35, associates with dynein light chains similar to HSV1 (73).  Bidirectional 
transport towards and away from the nucleus allows fine-tuning and precise delivery 
of capsids to avoid unproductive situations, such as accumulations at the 
microtubule organzing centers (70).  For DNA-tumor viruses it may ensure nuclear 
targeting in cells with divergent orientations of microtubules, such as polarized 
epithelial cells where microtubule minus ends are near the apical membrane, or 
basal cells where minus ends are near the nucleus.   
 
 
3.1. Viral determination of the transport direction or no transport bias? 
There are several possibilities how viruses might achieve their delivery to the nuclear 
membrane.  One is that they themselves define a transport preference by exposing 
proteins on the capsid that preferentially associate with a plus end or a minus end 
directed microtubule motor (74).  For example, the gamma-herpesvirus murine 
herpesvirus 4 which lacks the ORF75c tegument protein failed to be transported to 
the nucleus of murine cells although it was delivered into the cytosol (75).  Incoming 
HSV1 capsids preferentially recruit the dynein/dynactin motor complex as opposed to 
a plus end-directed motor, whereas newly assembled capsids recruit a periphery 
directed motor (76, 77).   
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An important question is the nature of the viral binding partner for motor proteins. 
Limited proteolysis of incoming HSV capsid or tegument proteins is part of a 
stepwise uncoating programme to make virions competent for engagement with 
cytoplasmic motors, such as the minor capsid protein VP26 or the tegument protein 
UL36 (VP1/2) (78).  For incoming viruses, it was suggested that proteasomal 
degradation but not ubiquitin is required for HSV localization to the nucleus (79).  
Alternatively, cytoplasmic processing of incoming capsids might make them 
competent for docking to the nuclear pore complex (NPC) as observed shortly after 
infection (64).  This suggests that nuclear accumulation occurs by retention, not 
requiring a transport bias.  In support of this, incoming Ad2/5 particles were found to 
be enriched at the nucleus in certain cell types without a detectable transport bias to 
the nucleus (67).   
 
3.2. Regulated transport 
Other aspects of cytoplasmic virus transport are subject to regulation by cell 
signalling.  It has been observed, for example, that signalling through protein kinase 
A and p38/MAPK enhanced the nuclear delivery of incoming Ad2/5 by stimulating 
minus end–directed transport (66).  Likewise, the activation of Rac1 during Ad2/5 
entry, which stabilizes peripheral microtubules (80) increased the loading of Ad2/5 to 
microtubules (81).  This is consistent with the observation that microtubule stabilizing 
compounds at very low concentrations enhanced nuclear targeting of Ad2/5 (82), 
and incoming Ad2/5 stabilized microtubules (83).   
 
Similar results have also been reported for KSHV, which activates Rho GTPases 
(84).  Activation of RhoA and Rac GTPase alters the dynamics by increasing the 
acetylation of microtubules thereby enhancing the dynein motor dependent transport 
of KSHV to the nucleus.  Interestingly, both Ad2/5 and KSHV use RGD peptides in 
one of their virion proteins to bind integrins for upstream signalling and endocytic 
uptake (46, 85, 86).  Integrin activation by the incoming viruses may lead to 
activation of Rho GTPases and PI3K activation (87), and local stabilization of 
microtubules, and thereby enhance the loading of viruses to the tracks.  It is possible 
that similar mechanisms are used by EBV, which encodes BFRF3, a homologue of 
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the HSV UL35 (VP26) capsid protein which associates with dynein light chains (73).  
The upstream signalling events for EBV are however not known, despite the notion 
that EBV enters B-cells through an endocytic pathway and fuses with the endosomal 
membrane at low pH (88, 89).  
 
Although the mechanisms of motor loading to the cytosolic virus particles are not 
known, components of the dynein motor in complex with the dynactin subunit have 
been observed on a number of cytoplasmic DNA-tumor viruses, including 
adenoviruses, herpesviruses, and papillomaviruses (67, 69, 90-93).  Interestingly, 
interference with the dynein/dynactin motor not only reduced viral transport towards 
the nucleus, but also decreased the transport rate to the periphery in some 
instances.  This suggests that dynactin and components of the dynein motor 
complex enable high activities of both dynein and kinesin motors on DNA-tumor 
viruses.  This interpretation is supported by trafficking studies of cellular cargoes 
where dynactin interference inhibited bidirectional (94), and overexpression of 
p50/dynamitin reduced both dynein- and kinesin II-mediated transport of 
melanosomes in Xenopus laevis (95).  Possibly, yet unknown proteins coordinate the 
activities of minus and plus end directed motors on the viral cargo, as suggested for 
lipid droplets in drosophila (96), or bidirectional transport is simply a consequence of 
the properties of the motors, as suggested for the transport of peroxisomes (97).   
 
4. From microtubules to the nucleus 
 
Incoming DNA-tumor viruses can reach the nuclear envelope by several 
mechanisms.  One is that the viruses must pass through the microtubule-organizing 
center (MTOC) (pathway A, Fig. 1), or that they detach from the microtubules 
proximal to the nucleus (pathway B, Fig. 1).  Detachment could, for example, occur 
by virus modification at the MTOC, or by an activity gradient of a nuclear factor 
leading to motor detachment from the tracks or the virus.  For Ad2/5 it has been 
shown that treating cells with inhibitors or siRNAs against the nuclear export factor 
CRM1 reduced the targeting of incoming Ad2/5 to the nucleus but did not affect viral 
transport on microtubules (98), and this requires the capsid protein hexon as 
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suggested by antibody interference (69).  CRM1 or a nuclear protein exported by 
CRM1 to the cytoplasm could hence provide a cue for virus detachment from 
microtubules.  Alternatively, CRM1, which binds Nup214/CAN could be involved in 
maintaining a functional binding site for the virus on the NPC.   
 
A second possibility to localize viruses to the nucleus is by stochastic detachment 
from microtubule tracks and cytoplasmic diffusion of the free particles until a binding 
site at the nuclear envelope, for example the NPC is reached.  This mechanism 
would be expected to be less rapid and less efficient than regulated detachment.   
 
A third, intermediate strategy is to detach the incoming DNA-tumor viruses from 
microtubules directly at the NPC thereby bypassing a diffusion step through the 
cytoplasm.  This model is attractive because the most distal NPC protein RanBP2 
(NUP358) has a binding site for microtubules (99), and could thereby connect 
cytoplasmic transport with nuclear import.  In this model viruses could either traffic all 
the way to the minus ends of microtubules near the centrosome, and revert transport 
direction towards the periphery to approach the nuclear envelope, or they could 
directly reach the nucleus by microtubules that lead from the periphery to the 
centrosome in close proximity to the nuclear envelope.   
 
A fourth possibility to access the nucleoplasm has been suggested for 
polyomaviruses.  These viruses are targeted to the endoplasmic reticulum and 
nuclear envelope lumen, from where they could penetrate the inner nuclear 
membrane (59, 100).  To what extent this unconventional pathway into the nucleus is 
used is, however, unknown.  Infectious incoming SV40 particles have been found in 
the cytosol on the other hand (reviewed in 101, 102) which implies that these viruses 




5. The nuclear pore complex - gate keeper of nucleocytoplasmic 
exchange 
 
DNA-tumor viruses infect nondividing cells and effectively utilize and manipulate the 
NPC.  NPCs are large macromolecular complexes, which control all known 
nucleocytoplasmic exchange of nondividing cells (reviewed in 103, 104).  There are 
multiple pathways for a large variety of cargoes through the NPC.  The general 
transport mechanism involves affinity gating on natively unfolded phenylalanine-
glycine (FxFG and GLFG) rich nucleoporins (NUPs, 105, 106, 107).  The affinity of 
transport receptors to the natively unfolded proteins provides selectivity for passage 
of the receptor-cargo complex through the NPC.  Stability and hence directionality of 
the receptor-cargo complex is controlled by the small GTP binding protein Ran (108).   
 
Within the NPC, the cytoplasmic filament protein Nup214/CAN and its associated 
protein Nup88 are involved in nuclear export of preribosomal complexes (109), and 
NES bearing proteins (110).  The cytoplasmic filament protein RanBP2/Nup358 
provides a docking platform for export complexes that are being disassembled, and 
for binding of cargo-free export receptors before they return to the nucleus (111).  It 
is also involved in import of NLS containing proteins, and its absence can be 
compensated by overexpression of import receptors (112).  In single round import 
reactions, neither RanBP2 nor Nup214/CAN are required for import of model 
proteins (113).  This supports the notion that NPC proteins, and in particular the FG-
repeat proteins have a high degree of redundancy (114).   
 
Finally, an important aspect of NPC function for DNA-tumor virus infections is that 
the pore diameter can be gated.  Kinetic studies have shown that within time frames 
typical for the entry phase of most viruses, the permeability diameter of the pore is in 
the range of 40 nm (115).  Although this is still too small for the passage of 
adenovirus, herpesvirus, or papovavirus (polyoma and papilloma) capsids, it is large 




6. Adenovirus docks and disassembles at the NPC, and releases 
the viral chromatin into the nucleus 
 
6.1. Adenovirus disruption 
In vitro and in vivo studies have shown that Ad2/5 bind to NPCs independently of 
cytosolic factors including NLS-containing proteins or nuclear import or export 
receptors (116, 117).  The major viral capsid protein hexon binds to the NPC protein 
Nup214/CAN located at the base of the cytoplasmic filaments.  This is reminescent 
of the Stat1 transcription factor binding to FG-nucleoporins Nup153 and Nup214 
(118).  Unlike Stat1, only 5% of the incoming hexon is found to be imported into the 
nucleus (119).  This is equivalent to the amount of one facette of the icosahedral 
capsid, and indicates that hexon itself does not have a functional NLS.  Accordingly, 
newly synthesized hexon protein enters the nucleus for viral capsid assembly only by 
chaperone-mediated folding (120) and binding to the nucleophilic protein VI (121, 
122).  Noteably, the large majority of incoming protein VI remains within endosomes 
(123) where it supports virus escape to the cytosol (47, 124).  The NPC-docked 
virions bind the highly mobile nuclear histone H1 (125), either via the acidic clusters 
of hexon facing towards the outside of the virion (126), or the viral DNA (Fig. 2).  This 
together with the H1-import factors importin (karyopherin) β  and importin 7, and 
additional factors contributes to capsid disruption and uncoating of the DNA-
nucleoprotein complex for import (117, 127).   
 
6.2. Nuclear import of adenovirus DNA associated proteins 
The viral chromatin enters the nucleus, yet the composition of the core, which is 
translocated through the NPC is not well defined.  The covalent interaction of the 
preterminal protein (pTP) with the 5’ ends of the viral genome predicts that the pTP is 
imported together with the DNA (128) (Fig. 2).  It is also likely that pVII and possibly 
histone H1 accompany the DNA through the NPC (117, 129).  In contrast, the 
composition of the core in the virus is well known.  It is made up of four viral proteins, 
protein V (pV, 368 amino acids, 157 copies per genome (130)), pVII (174 amino 
  13 
acids, about 800 copies per genome, (131)), mu (19 amino acids, 132)) and two 
copies of the terminal protein (671 amino acids) covalently attached to the 5' ends of 
the linear viral DNA (133).   
 
pV, pVII and mu are positively charged and condense the viral DNA.  The most 
abundant core protein pVII is tightly bound to the DNA in a manner similar to the core 
histones of eucaryotic chromatin (134), and remains associated with the viral DNA 
throughout the early phase of the viral life cycle (129, 135).  It is thought to attenuate 
viral gene expression, and is associated with the chromatin-modifying complexes 
SET and INHAT.  The precursor of pVII has basic NLS sequences that target the 
protein to the nucleus by interacting with importin alpha/beta (136, 137).  It has also 
been shown that pVII isolated from recombinant E. coli is imported into the nucleus 
of digitonin permeabilized cells by binding to the import factor transportin which 
recognizes M9-type sequences (137).  Whether pVII contains an M9-like sequence is 
unknown.  In vitro assays further suggested that nuclear import of the viral DNA 
required transportin, as it could be competed for by excess of soluble M9-GST fusion 
proteins (137).  Surprisingly, an excess of pVII was not able to compete for DNA-
import which suggests that pVII is not sufficient.  If transportin is involved in nuclear 
import of the incoming viral DNA and infection remains unknown.  It is also unknown 
if and how the terminal protein is involved in import of the viral DNA (128).   
 
Regardless, the incoming viral DNA-protein complex is remodeled in the nucleus, 
which involves several host factors of the chromatin remodeling complex, template-
activating factor-I (TAF-I), TAF-II, TAF-III and the acidic protein pp32 (138, 139).  
TAF-I forms a ternary complex with pVII (129, 140), and this is required for rapid 
onset of early viral gene transcription as suggested by siRNA knock-down 
experiments (138).  Later in the infection cycle, nucleophosmin/B23 interacts with 
newly synthesized precursor of pVII and suppresses aggregation of viral DNA with 
core proteins in the nucleus, and thereby supports viral assembly (141).   
 
Unlike pVII and terminal protein, the other core protein pV is less tightly bound to the 
DNA, and may be released before or during DNA import into the nucleus, as 
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suggested by chromatin immunoprecipitations (142).  It is not known if pV enters the 
nucleus on its own or in complex with other factors (143), or if it stays in the 
cytoplasm in association with the mitochondrial protein p32 implicated in ARF-
mediated apoptosis (144, 145).  Remarkably, a pV knock-out virus is viable in the 
presence of compensatory mutations in the mu protein (146).  This suggests that pV 
has no unique functions in the replication cycle of mastadenoviruses, at least in 
cultured cells, which is further supported by the observation that pV does not occur in 
atadenoviruses, aviadenoviruses and siadenoviruses.   
 
 
7. Herpesviruses dock to the NPC and release their DNA into the 
nucleus 
 
7.1. Herpes simplex virus type 1 docking to the NPC 
Similar to adenoviruses, herpesviruses uncoat their DNA at the NPC (see Fig. 2).  
This strategy precludes that the naked viral chromatin travels through the cytoplasm, 
which could trigger DNA-sensing innate immune responses including the TBK-IRF 
pathway or inflammasome (147, 148).  In vitro experiments showed that HSV-1 
capsids purified from extracellular virions by detergent and high salt treatments 
bound to NPCs of rat liver nuclear envelopes depending on soluble importin β, Ran-
GTP and other factors (149).  Experiments with the hamster mutant cell line tsBN2 
(150) at the restrictive temperature confirmed that the Ran guanine nucleotide 
exchange factor RCC1 (regulator of chromosome condensation 1) was required for 
genome delivery to the nucleus or gene expression (151).   
 
Although the components of the viral capsid recognized by importin beta are not 
known, it has been shown trypsin-treated capsids, which lost the inner tegument 
proteins including UL47 (VP13/14), UL48 (VP16) and UL49 (VP22) poorly bound to 
the isolated nuclei.  While the UL48 (VP16) transcription factor associated with UL49 
(VP22) and supported virus assembly (152), the knock out of UL49 (VP22) had no 
effects on the expression levels of the immediate early viral protein ICP0 (153), 
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indicating that UL49 (VP22) has no important role for nuclear import of HSV1 DNA.  
Interestingly, the 32 kDa tegument protein UL14 has been implicated in enhancing 
nuclear import of UL48 (VP16), and it enhanced nuclear targeting of incoming HSV1 
(154).  In the nucleus, it forms a regulatory complex with HCF1 and the POU-domain 
transcription factor Oct1, and thereby activates transcription of immediate early viral 
genes (155).  It is possible that UL14 is involved in cytoplasmic transport or docking 
of incoming virions to the NPC, and thereby facilitates the uncoating of the viral DNA 
for nuclear import.   
 
7.2. Herpes simplex type 1 mutants dissect uncoating and nuclear import 
The recent developments of viral mutants have allowed progress in understanding 
viral mechanisms of capsid disassembly.  Experiments with the classical HSV1 
temperature sensitive mutant tsB7 and a similar pseudorabies virus mutant indicated 
that viral DNA is released at the NPC (156, 157).  At the non-permissive temperature 
tsB7 capsids containing DNA accumulated at the NPC, whereas upon temperature 
shift, DNA was released.  This was consistant with early electron microscopy studies 
showing that empty capsids of incoming viruses accumulated at the nuclear 
membrane and persisted for several hours (158, 159).  Mutational mapping of tsB7 
showed that the UL36 gene encoding the VP1/2 tegument protein was involved in 
releasing the DNA from the capsid (160).  UL36 (VP1/2) is conserved in beta- and 
gamma- herpesviruses (reviewed in 161).  UL36 (VP1/2) together with UL37 and 
UL25 is one of the innermost capsid associated tegument proteins that remain 
associated with the incoming capsids until docking at the NPC.  UL36 deletion 
mutants failed to spread the infection to uninfected nuclei in experimentally induced 
syncitia indicating that UL36 was required for capsid transport to, or DNA import into 
the nucleus (162).  Interestingly, proteolytic cleavage of VP1/2 was required for DNA 
import into the nucleus but not for capsid docking to the NPC (163).   
 
While UL37 was not required for delivery of HSV1 DNA into the nucleus (162) – 
although it was involved in pseudorabiesvirus transport to the nucleus (164), another 
inner tegument protein UL25 was specifically implicated in DNA uncoating, as 
indicated by the temperature sensitive HSV1 ts1249 mutant which had an uncoating 
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defect at the restrictive temperature but was transported to the nucleus (165).  
Interestingly, the EBV may use similar mechanisms since its protein BVRF1 is a 
homologue of UL25 (166) which remains capsid associated and localizes to 
microtubules as well as to nuclear membrane with incoming capsids (167).  Since 
UL25 is also required for DNA packaging and associates with the portal complex at a 
single capsid vertex (168), it is possible that the DNA is extruded through the portal 
structure of the capsid (169-172).  The portal is part of a ring structure made up by 
the UL6 protein, and has a 5 nm pore through which the viral DNA is packaged into 
the procapsid during replication of both herpesviruses and double-stranded DNA 
bacteriophages (173).  UL6 is conserved among other alpha- herpesviruses, such as 
varizella zoster virus (VZV), which causes varicella (chickenpox, primary infection) 
and zoster (shingles, a secondary infection upon reactivation of VZV from latency).  
Future measurements of herpesvirus DNA uncoating on isolated nuclear envelopes 
in combination with specific orientations of single virus particles may unveil if the 
portal needs to be oriented towards the NPC for DNA release into the nucleus or if 
the orientation of the particles can be random.  All this provides strong evidence that 
the inner tegument proteins UL25 and UL36 (VP1/2) and the portal are parts of 
capsid-associated complexes that interact with the NPC, and trigger the release of 
viral DNA from the capsid.   
 
In the herpesvirus capsid, the DNA is tightly packed in a paracristalline array and 
thought to be protein-free, similar to bacteriophage DNA (174).  Studies of DNA 
ejection from bacteriophages had argued that DNA release can be attenuated by 
surrounding osmotic pressure implying that the process is independent of ATP 
consuming enzymes, such as motor proteins (175).  Recent studies have extended 
this concept showing that DNA condensation by osmotic stress and DNA binding 
proteins enhances the ejection process from the phages (176).  For HSV1, atomic 
force microscopy experimentation suggested that the incoming genome is 
translocated through the NPC as a condensed rod-like structure with a diameter of 
35-40 nm and a length of 130-160 nm (177).  It is thus possible that the herpesvirus 
DNA picks up DNA condensing proteins, such as cellular histones after its release 
from the capsids.  Histones would not only condense and neutralize negative 
charges on the DNA backbone, they would also be a template for import factors, 
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such as importin beta- and importin 7 (178), and thereby increase the probability for 
DNA passage through the NPC, as suggested for adenovirus DNA (117).  That 
histones could be involved in herpesvirus infection is also supported by the finding 
that incoming viral DNA was complexed with histones as early as 1 h post infection, 
although it is not known how and where histones associate with the incoming DNA 
(179).  Whether tegument proteins with functional NLSs, such as UL36 (VP1/2) (180) 
mediate nuclear import of the DNA is not known.   
 
 
8. Nuclear import of papillomaviruses and polyomaviruses 
 
Human papillomaviruses (HPV) uptake is a slow process and not well defined, 
although it seems to be acid dependent (52, 61, 181, 182).  Some HPVs bind to 
heparansulfate-proteoglycans (183) and possibly secondary receptor(s), such as 
alpha-6 integrin, laminin or tetraspanin proteins (184, 185).  Factors and signals that 
lead to nuclear import of nonstructural and structural HPV proteins are listed in Tab. 
2.  It is unknown, however, how the viruses reach the cytosol, and the genomes 
imported into the nucleus.  
 
Similar to papillomaviruses, the polyomaviruses SV40, JC virus and BK virus access 
the nucleus after endocytic uptake (see Fig. 2) (186-188).  SV40 has a double-
stranded closed circular DNA of 5000 base pairs, three structural proteins VP1, VP2, 
and VP3, and four core histones, H2A, H2B, H3 and H4 (189).  VP1 forms 72 
pentameric capsomers (190), incorporating the minor proteins, VP2 and VP3 that are 
thought to contact the minichromosome and the VP1 pentamer (191).  It is thought 
that polyomaviruses undergo limited conformational changes at the plasma 
membrane, in endosomes or the endoplasmic reticulum (ER).  In the case of SV40, 
the reducing environment and the protein folding machinery of the ER may lead to 
the release of DNA-containing subviral particles into the cytosol (59).  This may also 
lead to the exposure of the NLS in the amino-terminus of the capsid protein VP1 
(reviewed in 101, 192).   
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Experiments with microinjected SV40 favor the notion that infectious viral DNA 
passes through the cytosol (193).  SV40 subviral particles were found to be imported 
into the nucleus, as concluded from the observation that the injection of neutralizing 
antibodies against the VP1 amino-terminus or against VP3 into infected cells blocked 
infection (194) (Fig. 2).  These subviral particles are thought to contain the core 
histones, yet the histone-complexed minichromosomes were poorly targeted to the 
nucleus (194).  This indicates a role for the VP1,2,3 proteins in cytoplasmic transport 
or NPC binding.   
 
Interestingly, VP1,2,3 can each be independently imported into the nucleus (195).  
VP1 has a bipartite amino-terminal NLS whereas VP2 and VP3 have a classical 
SV40 T-antigen-like signal in the carboxy-terminus (196).  Recently, cytosolic virus 
was found to bind importin α and β (197).  Only a small fraction of the incoming DNA 
was, however, recovered in immune complexes with VP1 and the minor capsid 
protein VP3.  The DNA was sensitive to DNase, unlike the DNA of intact purified 
SV40 particles.  This suggests that SV40 entry into the cytosol is slow, rather 
inefficient, and coupled to partial DNA uncoating.   
 
A similar process of NLS exposure and importin binding may operate for JC virus 
entry, which may reflect a similar use of NLS sequences for nuclear import of newly 
synthesized proteins (198).  Unlike SV40, JC virions were apparently imported into 
the nucleus in a more intact form than the SV40 subviral particles, as suggested by 
analyses of particles loaded with free fluorescent dye molecules (199).  
 
 
9. Nuclear import of hepadnaviruses 
 
HBV is an enveloped DNA-virus with an icosahedral capsid of 180 or 240 core 
proteins (200).  HBV infects primary human hepatocytes and a few cell lines at low 
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efficiency, which makes it difficult to study the infectious entry of this virus.  
Lipofection has been used to deliver HBV capsids into the cytoplasm (201).  In these 
experiments capsids were transported by microtubule dependent motors to the 
nuclear membrane where they bound to NPCs, and they released their genome into 
the nucleus.  These results were similar to studies with duck hepatitis virus (dHBV) 
(55, 202, 203).  dHBV core proteins have an internal NLS as the carboxy-terminus of 
the HBV core (204).  A dHBV knock-out mutant lacking the core NLS was not found 
at the NPC suggesting that this NLS was directly or indirectly required for capsid 
localization to the NPC.  Biochemical studies suggested that attachment of HBV 
capsids to the NPC and transport through the NPC involved importins and the NLS in 
the carboxy-terminus of the HBV core protein (205, 206) (Fig. 2).  In native capsids, 
this NLS is not exposed at the surface, which implies that conformational changes of 
the capsid during entry are required for importin binding, capsid uncoating and DNA 
import into the nucleus (207).  An alternative nuclear import model for HBV 
suggested that the capsids could very transiently interact with the NPC in an 
importin-independent manner (208).  These results suggested that binding of HBV 
initially occurs on one of the cytoplasmic filaments, off-centered from the central axis 
of the NPC towards the edges by about 45 nm.  How uncoating of the viral DNA 
occurs is unknown. 
 
 
10. Conclusions and outlook 
 
Nuclear import of DNA-tumor virus genomes depends on cell type and virus specific 
steps, such as binding to receptors, uptake and signaling into cells.  Subsequent 
events, including rupture of endomembranes, cytoplasmic transport, uncoating and 
nuclear import of the genome involve virus family-specific mechanisms, and can be 
studied with prototypic DNA-tumor viruses and the tumor viruses.  In the past years, 
signals and host factors for nuclear import have been identified for a considerable 
number of DNA-tumor virus capsid proteins.  These studies have so far not resulted 
in novel anti-viral treatments, possibly due to a strong similarity of viral protein import 
with host protein import into the nucleus.  Ongoing analyses of viral genome 
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uncoating and nuclear import may, in contrast, identify exquisite host factors for viral 
DNA import.  If such factors are dispensible for normal cell functions in cells that are 
infected by DNA-tumor viruses, they constitute a new class of targets for anti-viral 
compounds.  Mechanistic cell biological analyses combined with interference 
experiments in cells and animal models will be necessary to elucidate the complex 
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Figures and Tables 
 
Fig. 1: Prototypic entry pathway of a DNA-tumor virus 
An intact virus particle (red) attaches to a primary and secondary receptor(s), which 
can elicit signalling into the cell.  Viral transport on the cell surface is followed by 
confinement and endocytosis (or direct penetration of the plasma membrane in some 
cases), which coincides with initiation of a stepwise viral uncoating programme (or 
membrane fusion).  Virus is taken into primary vesicles and transported to 
intracellular compartments where penetration to the cytosol occurs.  Bidirectional 
microtubule-dependent transport moves viruses to the microtubule-organizing center 
(MTOC) (A), or along the nuclear envelope (B), from where viruses reach the nuclear 
pore complex (NPC) by unknown mechanisms.  They bind to the NPC, uncoat their 
DNA and release it into the nucleus.  
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Fig. 2: Disassembly and nuclear import strategies of DNA-tumor viruses 
Adenoviruses, herpesviruses, polyomaviruses and hepadnaviruses import cores with 
linear or circular genomic DNA and viral proteins into the nucleus of post-mitotic 
cells.  A) Schematic representation of four prototypic nuclear import mechanisms for 
viral cores containing genome and viral proteins.  Adenoviruses employ a capsid 
disruption strategy at the nuclear pore complex to release the core from the capsid.  
Herpesviruses use a capsid unplugging mechanism, and polyomaviruses and 
hepadnaviruses a mechanism which delivers capsids or subcapsid particles into the 
nucleus.  The table of panel B) lists the NLS-containing viral core proteins and the 






The most common mammalian DNA-tumor viruses 
___________________________________________________________________________________________________________________________________________________________________________________ 
 
Family  Genus Species   Serotype     Size (nm) Oncogene  Tumor   References 
___________________________________________________________________________________________________________________________________________________________________________________ 
 
Adenoviridae         90 E1A, E1B, E4orf1    (133, 210) 
  Mastadenoviruses  Ad12        Experimental tumors in rodents (7, 8) 
     Various serotypes from subspecies A, B, C, D    Candidate tumor viruses  
 
 
Herpesviridae         150       
  Alpha-herpesviruses 
   Mardivirus  Gallid herpesvirus 2 (Marek’s disease virus)        (13) 
  Gamma-herpesviruses            (211) 
   Lymphocryptovirus Human herpesvirus 4 (HHV4, Epstein-Barr virus, EBV)  EBNA-2,3   Burkitt’s lymphoma  (212) 
   Rhadinovirus Saimiriine herpesvirus 2 (Herpesvirus saimiri)        (213) 
     Murid herpesvirus 4 (Murid herpesvirus 68)        (214) 
     Human herpesvirus 8 (HHV8, Kaposi’s sarcoma virus KSHV) K1, vGPCR Kaposi’s sarcoma  (215) 
 
 
Papillomaviridae         55 E6, E7  Squamous cell carcinomas (216, 217) 
  Alpha-papillomaviruses Human papillomavirus 16, 18, 31, 45 
     Rhesus papillomavirus type 1 (RhPV1) 
  Gamma-papillomaviruses Human papillomavirus 4 
  Delta-papillomaviruses  Bovine papillomavirus 1, 2 
     European elk papillomavirus 
  Kappa-papillomaviruses Cottontail rabbit papillomavirus 
  Lambda-papillomaviruses Canine oral papillomavirus 
  Mu-papillomaviruses  Human papillomavirus 1 
  Xi-papillomaviruses  Bovine papillomavirus 4 
 
 
Polyomaviridae         40 T-antigen     (189) 
   Simian virus 40 (SV40)        Sarcomas in juvenile hamsters (218) 
   BK virus          Brain tumors  (219) 
   JC virus          Gliomas, medulloblastomas (220) 
   Merkel cell polyomavirus (MCPyV)       Human skin cancer  (20) 
   Murine polyomavirus         Mesotheliomas  (221) 
   Hamster polyomavirus         Cutaneous tumors  (222) 
 
 
Hepadnaviridae         30-34 HBx  Hepatocellular carcinoma (223) 
  Orthohepadnaviruses  Hepatitis B virus (HBV) 
Woodchuck hepatitis virus (WHV)      animal model virus  (224) 
 
 
Poxviridae         200x300      (225) 
Chordopoxviruses             (226) 
   Molluscipoxviruses Molluscum contagiosum virus      Epidermal tumors  (227) 
   Leporipoxviruses Shope fibroma virus     SFGF  Benign cutaneous tumors (228) 
   Yatapoxviruses Yaba monkey tumor virus      Subcutaneous histicytomas (229) 
   Avipoxviruses Fowlpoxvirus          (230)
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Table 2: Nucleocytoplasmic shuttling of human papillomavirus proteins 
 
Protein     Import    Export  Function    Literature 
 
Non-structural, regulatory  
E1     Imp α3/4/5 / E2   CRM1  DNA strand separation   (1-6)  
E2     Strong NLS in hinge region   E1 assembly, tethering factor  (1, 6, 7) 
           Transcriptional activator 
E4     Putative classical NLS    Host replication inhibition  (8, 9) 
           Interaction with keratin network 
E5     Cytoplasmic protein    Growth stimulation   (10) 
E6      Various importins  CRM1?  Inactivation of p53   (11, 12) 
E7     Ran-dependent, large NLS NES  Inactivation of tumor supressors (13, 14) 
     Importin-independent?   
 
Structural, capsid  
L1      α2/β1      Main capsid component  (15-18) 
L2     α2/β1, β2, β3, Hsc70    Membrane destabilisation  (15, 19-22) 
 
Literature for table 2: 
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2. Bian XL, Rosas-Acosta G, Wu YC, Wilson VG. Nuclear import of bovine papillomavirus type 1 E1 protein is mediated by multiple alpha importins and is negatively regulated by phosphorylation  
near a nuclear localization signal. J Virol 2007;81(6):2899-2908. 
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